Quality of life and patient benefit following transition from methotrexate to ustekinumab in psoriasis

M. Augustin, C. Blome, C. Paul, L. Puig, T. Luger, J. Lambert, S. Chimenti, G. Girolomoni, K. Kragballe, D. Naessens, P. Bergmans, P. Smirnov, J. Barker, K. Reich

Research output: Contribution to journalArticleResearchpeer-review

7 Citations (Scopus)


© 2016 European Academy of Dermatology and Venereology Background: TRANSIT (NCT01059773) compared immediate and gradual transition from methotrexate to ustekinumab in psoriasis patients via multiple measures, including patient-reported outcomes. Objective: To evaluate patient perception of treatment benefits in TRANSIT. Methods: A total of 489 psoriasis patients received ustekinumab, with immediate cessation of methotrexate (Arm 1) or 4 weeks’ overlap with decreasing methotrexate dose (Arm 2). Ustekinumab was administered at weeks 0, 4, 16, 28 and 40. Dermatology Life Quality Index (DLQI), EuroQol 5-item (EQ-5D), visual analogue scale (VAS) valuation technique and patient benefit index (PBI) were employed. Mean global PBI and sub-scores were calculated from the sum of the benefit items weighted by their respective relevance at baseline. Patient-relevant benefit was defined as PBI ≥1 (scale: 0 [no benefit] to 4 [maximum benefit]). Correlations of global PBI with Psoriasis Area and Severity Index (PASI) and DLQI were examined. Results: Relationships between PBI and clinical data were evaluable in 340 patients. The most important treatment goals at baseline included: ‘be healed of all skin defects’, ‘have confidence in therapy’, ‘get better skin quickly’ and ‘regain control of the disease’. Benefit in PBI global score was achieved at week 4 by 93% of patients in Arm 1 and 91% in Arm 2. Global PBI scores increased in both Arms between weeks 4 and 52. Global PBI correlated weakly with PASI change from baseline (correlation coefficient range: −0.22 to −0.40), and moderately with DLQI (−0.29 to −0.54). Overall DLQI score was lower than baseline at all times; and the percentage of patients with an overall score of 0 or 1 increased with time. Correspondingly, EQ VAS scores increased with time. DLQI and EQ VAS results were similar between arms. Conclusions: Regardless of the strategy for transitioning from methotrexate, ustekinumab was associated with rapid and sustained improvement in patient-reported outcomes. PBI appears a suitable tool for assessing patient-relevant treatment benefits in psoriasis patients.
Original languageEnglish
Pages (from-to)294-303
JournalJournal of the European Academy of Dermatology and Venereology
Issue number2
Publication statusPublished - 1 Feb 2017


Dive into the research topics of 'Quality of life and patient benefit following transition from methotrexate to ustekinumab in psoriasis'. Together they form a unique fingerprint.

Cite this